Introduction
The permeability of the placenta for parathyroid hormone (PTH) was first postulated by MEINERT 1898 [19] . He and later on BRONSKY [7] reported relief of tetany during pregnancy in women with hypoparathyroidism prior to conception. The authors proposed that the relief of tetany was by transfer of fetal PTH to the mothers.
The permeability of the placenta for PTH was studied in vivo in several animal experiments [9, 11, 13, 16, 18, 22, 30] . PTH transfer was observed, but the transfer was inconsistent and the amounts of transferred hormone were very small. The authors concluded that PTH does not cross the placenta in either direction.
Recently we have reported that PTH (amino acids 35 -84) traverses the human placenta at term in both directions. These effects were studied in an in vitro placenta perfusion model [4] . The transferred PTH quantities (up to 5% of the perfused PTH) were determined radioimmunologically and consequently it was not possible to exclude that only PTH fragments or metabolites were transferred.
In this study we have investigated the placental transfer of three PTH fragments in vitro. The perfused and transferred fragments were identified by three different physiochemical methods. An abstract of this work has been published previously [5] .
Materials and methods

Placental perfusion
Placentae at term were obtained immediately after delivery. A cotyledon approximately 3-4 cm as preparated for perfusion according to the method and the perfusion model developed by HENRICHS and WOLF [14] , which was a modification of the model of SCHNEIDER [27] .
PTH extract was infused into the fetal artery (feto-maternal transfer) for 20 minutes. Perfusate samples from the maternal side (MS) and the fetal vein (FV) were taken at intervals of 3 and 5 minutes over a period of 40 min after the start of perfusion. Complete separation of samples from the maternal and fetal sides was proved by dextranblue added to the perfusate. Furthermore, PTH extract was infused into the intravillous space for 20 min. Perfusate samples from fetal and maternal vein were taken as above. The PTH fragments assayed for the perfusion were: The transfer of the labelled fragments was determined by counting the activity in the samples collected at the opposite site. The transfer of nonlabelled hormone was determined by radioimmunoassays (35 -84: Institut National des Radioelements, Belgium, 44-68: Paesel, Germany).
The identification of fragments was achieved as follows: a) High-pressure-liquid chromatography (HPLC) (Waters Inc). Synchropak RPR 10 μ, 100 A in 250 4.6mm stainless-steel columns (Bischoff, Germany) were used. Separation was carried out at 20 °C, with 0.1 m phosphate buffer (pH 2.1) as primary solvent and acetonitril as organic modifier at constant flow rate of 1 ml/min and 220 nm UV adsorbance. The fractions were collected and the radioactivity of each measured in the gamma counter. b) Preparative-flat-bed electrofocusing (PEGG) was performed in a granulated gel (5ml 40% Servalyt pH 2-11,5 ml sample, 90 ml distilled water). The separated zones were collected and their activity measured in the gamma counter. c) Gel filtration (GF). For the gel filtration of sephadex columns G-25 900 16 mm (Pharmacia, Sweden) were used. The flow rate was 1.0 ml/min at 20 °C in phosphate buffer pH 7.5. Fractions were collected at 2ml. The activity in the collected fractions was measured. Dextranblue, cytochrome C and vitamin B were added as calibrating substances to each filtration.
RIA for PTH
The concentrations of PTH fragments 35-84 were measured by RIA of the C-terminal. The standard was bovine PTH, the antiserum was a rabbit antiserum directed against the C-terminal part (amino acids 35 -84) of the molecule. The standard curve covers the range 0.3 ng/ml -12,5 ng/ml. The intra-and interassay coefficients of variation were 7.2% and 10.2%. RIA for PTH 44-68:
The standard was synthetic PTH, the antibody was prepared in the goat against the amino acids 44-68 part of the hormone. The lower limit of sensitivity was 0.05 ng/ml. The intraassay coefficient of variation »was 11.2%.
Patients
Forty healthy pregnant women who were admitted to the University Maternity Hospital for delivery were studied. Informed consent was obtained from each. All infants were born at term by spontaneous vaginal delivery. Forty blood samples were obtained by venipuncture from mothers at delivery and from the umbilical cord by separate catheterization of the umbilical cord vein and artery. After centrifugation plasma samples were frozen at -20 °C until analyzed. The samples were collected from October 1981 through February 1982. Plasma samples of 169 normal adult volunteers (87 women and 82 men) ranging in age from 20 to 50 years were studied for reference.
Statistical methods
Results were expressed as median and range. Data were statistically evaluated using the Wilcoxon test for paired samples and Student'ttest for comparison of individual values. Correlations (r) were tested by linear regression analysis.
Results
The transfer of 125 I-labelled or nonlabelled PTH fragments was detected after 3 minutes of perfusion. The concentrations measured by RIA and/or counting of the radioactivity (CPM) rose during the perfusion up to 5% of the perfused concentration (figure 1). The retention times (rt) and isoelectric points (IP) of the perfused and transferred 125 I-labelled PTH fragments, determined by GF, HPLC and PEGG respectively, were identical.
On GF analysis the eluted labelled PTH fragments (35-84)*, (44-68)* and (65-84)* with molecular weights (MWt) of 6300, 3250 and 2450 respectively, showed positions which were consistent with the calibrating substances (dextranblue, cytochrom C and vitamin B with MWt of 2000000, 12300 and 1355, respectively). The results of the different separation methods for three fragments are given in figure 2.
We observed up to a 67% degradation of the PTH hormone during the passage of the placenta (from fetal to maternal side and vice versa) (figure 3). cantly lower than the maternal values at delivery (P < 0.001). There was a significant correlation between maternal and venous cord plasma PTH (r = 0.682, P < 0.001) (figure 4). 
Discussion
The permeability of mammalian placenta for PTH has been studied in vivo by different investigators. No transfer was found in animal experiments by HOSKIN et al [16] , SMITH et al [30] , LEHRMANN et al [18] , CARE et al [9], FLEISCHMAN et al [13] , NORTHROP et al [22] , and ERENBERG et al [11] . In contrast, when the data of SMITH et al [30] and NORTHROP et al [22] are reconsidered, it is evident that in some experiments the PTH concentrations in the fetus increased after injection of PTH into the pregnant animal and vice versa. However, the amounts of transferred hormone were very small and inconsistent and the authors concluded that PTH did not cross the placental barrier in either direction.
Intact PTH (amino acids 1 -84) has a molecular weight of above 10000. In the circulation, it is rapidly cleaved through receptors in the periphery. Circulating PTH, represents a heterogenous mixture of polypeptides with different molecular weights [8] . The low molecular weight fragments may traverse the placenta [28] easier than the high molecular fragments. In our studies we have demonstrated placental transfer of three different PTH fragments with molecular weights between 1500 and 7000 (figure 2).
Conversely, we have also observed up to 67% PTH (amino acids 35 -84) degradation during the passage through the placenta. This could explain the low amount of PTH transfer in the previously described animal experiments:
Placental transfer is dependent upon various factors, such as fat solubility, degree of ionization, possible existence of a transport mechanism and the PTH transfer also from calcium homeostasis. All these variables are not present under our experimental conditions. This hypothesis of the PTH transfer is in agreement with the measurements of PTH in plasma of maternal and umbilical cord vessels. We detected immunoassayable PTH in all maternal venous and arterial and venous umbilical cord plasma samples with a highly significant correlation between maternal and umbilical cord venous plasma concentrations (figure 4) [3] . All arterial and venous cord umbilical plasma values were lower than the maternal PTH values but within the range of normal adult values. These results are in accordance with the data \ofScHEDEWiE et al [26] , LEQUIN et al [17] , TSANG et al [31] , WATNEY et al [32] , and PITKIN et al [23] . On the contrary, FANCONI et al [12] , DAVID et al [10] , ROOT et al [25] , FLEISCHMANN et al [13] , REITZ et al [24] , HILLMANN et al [15] , and WIELAND et al [33] either could not detect PTH in cord blood or observed only very low concentrations.
The discrepancies of data from different investigators could be explained by the use of different antisera. The specific antisera in the radioimmunosassy determine different PTH fragments [2] . The lack of a PTH standard of human origin, the immunological differences between species, the fact that genuine glandular hormone is immunologically different from secreted hormone, and the lack of international standard material all may account for the divergence of results.
In this study we observed significantly higher PTH levels in the umbilical cord artery than in the vein. NORRIS [21] , MOSCA [20] , and ANAST [1] demonstrated that the fetal parathyroid glands develop during the first three embryonic months. SCOTHORN [29] showed that parathyroid function in the human fetus may be present as early as twelve to thirteen weeks of gestation.
In accordance with these authors, our results prove that the fetus at term secretes PTH into its plasma.
In summary the present study demonstrates the placental transfer of different PTH fragments in an in vitro perfusion model. The perfused and transferred fragments were identical. It was also observed, that human placenta, similar to the kidney and liver [6], degraded the hormone. The measured PTH concentrations in the umbilical cord vessels plasma as well as the significant correlation between PTH values in maternal and umbilical cord venous plasma supported the in vitro findings and led to the conclusion that PTH transfer also occurs in vivo.
The permeability of the human placenta for PTH fragments and its capacity to degrade the hormone suggests the importance of this organ in the calcium homeostasis during pregnancy.
Summary
We investigated the in vitro transfer of three parathyroid hormone (PTH) fragments (amino acids 35 -84, 44-68 and 65 -84) through human placenta at term. The perfused and transferred fragments were measured radioimmunologically and identified by three different methods: high-pressure-liquid chromatography (HPLC), preparative flat-bed electrofocussing (PEGG), and gel filtration (GF). The study demonstrated that PTH fragments traverse the human placenta. The transferred and perfused fragments were identical. We observed a significant degradation of the perfused hormone during the passage through the placenta in both fetal and maternal directions.
In addition, we measured the PTH concentrations on forty samples of maternal and umbilical cord artery and vein plasma obtained immediately after delivery. A highly significant correlation of PTH concentrations in the maternal and umbilical cord vessels was observed. These findings support the contention that human placenta at term is permeable for PTH fragments.
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